Postherpetic Neuralgia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Postherpetic Neuralgia – Pipeline Review, H2 2016’, provides an overview of the Postherpetic Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia

The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects

The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aestus Therapeutics, Inc.

ContraVir Pharmaceuticals, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Immune Pharmaceuticals Inc.

Jiangsu Hengrui Medicine Co., Ltd.

KPI Therapeutics, Inc.

Lpath, Inc.

Merck & Co., Inc.

Patagonia Pharmaceuticals, LLC

Pfizer Inc.

Phosphagenics Limited

Relmada Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Toray Industries, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Postherpetic Neuralgia Overview 9

Therapeutics Development 10

Pipeline Products for Postherpetic Neuralgia - Overview 10

Postherpetic Neuralgia - Therapeutics under Development by Companies 11

Postherpetic Neuralgia - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Postherpetic Neuralgia - Products under Development by Companies 16

Postherpetic Neuralgia - Companies Involved in Therapeutics Development 17

Aestus Therapeutics, Inc. 17

ContraVir Pharmaceuticals, Inc. 18

Daewoong Pharmaceutical Co., Ltd. 19

Daiichi Sankyo Company, Limited 20

Immune Pharmaceuticals Inc. 21

Jiangsu Hengrui Medicine Co., Ltd. 22

KPI Therapeutics, Inc. 23

Lpath, Inc. 24

Merck & Co., Inc. 25

Patagonia Pharmaceuticals, LLC 26

Pfizer Inc. 27

Phosphagenics Limited 28

Relmada Therapeutics, Inc. 29

Scilex Pharmaceuticals, Inc. 30

Teva Pharmaceutical Industries Ltd. 31

Toray Industries, Inc. 32

Postherpetic Neuralgia - Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 38

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(amitriptyline + ketamine hydrochloride) - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ATX-08001 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

bupivacaine hydrochloride - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

C-746 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

DWP-05195 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

funapide - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

FV-100 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

ketoprofen - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

lidocaine hydrochloride - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

lidocaine hydrochloride patch - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Lpathomab - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

mepivacaine hydrochloride - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

mirogabalin besylate - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

MK-8291 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

naltrexone hydrochloride - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

PATN-02 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

pregabalin CR - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

pregabalin SR - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

REL-1017 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

TRK-700 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

U-2902 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

zucapsaicin - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Postherpetic Neuralgia - Dormant Projects 84

Postherpetic Neuralgia - Discontinued Products 87

Postherpetic Neuralgia - Product Development Milestones 88

Featured News & Press Releases 88

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 88

May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias 88

Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized 89

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 90

Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires 90

Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido 91

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 91

Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia 91

Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 92

Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia 92

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 93

Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 94

Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 94

Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 95

Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 95

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

List of Tables

Number of Products under Development for Postherpetic Neuralgia, H2 2016 10

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Postherpetic Neuralgia – Pipeline by Aestus Therapeutics, Inc., H2 2016 17

Postherpetic Neuralgia – Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 18

Postherpetic Neuralgia – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 19

Postherpetic Neuralgia – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20

Postherpetic Neuralgia – Pipeline by Immune Pharmaceuticals Inc., H2 2016 21

Postherpetic Neuralgia – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 22

Postherpetic Neuralgia – Pipeline by KPI Therapeutics, Inc., H2 2016 23

Postherpetic Neuralgia – Pipeline by Lpath, Inc., H2 2016 24

Postherpetic Neuralgia – Pipeline by Merck & Co., Inc., H2 2016 25

Postherpetic Neuralgia – Pipeline by Patagonia Pharmaceuticals, LLC, H2 2016 26

Postherpetic Neuralgia – Pipeline by Pfizer Inc., H2 2016 27

Postherpetic Neuralgia – Pipeline by Phosphagenics Limited, H2 2016 28

Postherpetic Neuralgia – Pipeline by Relmada Therapeutics, Inc., H2 2016 29

Postherpetic Neuralgia – Pipeline by Scilex Pharmaceuticals, Inc., H2 2016 30

Postherpetic Neuralgia – Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 31

Postherpetic Neuralgia – Pipeline by Toray Industries, Inc., H2 2016 32

Assessment by Monotherapy Products, H2 2016 33

Assessment by Combination Products, H2 2016 34

Number of Products by Stage and Target, H2 2016 36

Number of Products by Stage and Mechanism of Action, H2 2016 39

Number of Products by Stage and Route of Administration, H2 2016 42

Number of Products by Stage and Molecule Type, H2 2016 44

Postherpetic Neuralgia – Dormant Projects, H2 2016 84

Postherpetic Neuralgia – Dormant Projects (Contd..1), H2 2016 85

Postherpetic Neuralgia – Dormant Projects (Contd..2), H2 2016 86

Postherpetic Neuralgia – Discontinued Products, H2 2016 87

List of Figures

List of Figures

Number of Products under Development for Postherpetic Neuralgia, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 33

Assessment by Combination Products, H2 2016 34

Number of Products by Top 10 Targets, H2 2016 35

Number of Products by Stage and Top 10 Targets, H2 2016 35

Number of Products by Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Routes of Administration, H2 2016 41

Number of Products by Stage and Routes of Administration, H2 2016 41

Number of Products by Molecule Types, H2 2016 43

Number of Products by Stage and Molecule Types, H2 2016 43

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports